1. Home
  2. WB vs TRVI Comparison

WB vs TRVI Comparison

Compare WB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weibo Corporation

WB

Weibo Corporation

HOLD

Current Price

$7.78

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$17.14

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WB
TRVI
Founded
2009
2011
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
WB
TRVI
Price
$7.78
$17.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
11
Target Price
$14.00
$21.55
AVG Volume (30 Days)
947.0K
3.0M
Earning Date
05-28-2026
05-05-2026
Dividend Yield
7.49%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.35
N/A
Revenue Next Year
$1.73
N/A
P/E Ratio
$5.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.09
$6.55
52 Week High
$12.96
$20.22

Technical Indicators

Market Signals
Indicator
WB
TRVI
Relative Strength Index (RSI) 55.60 49.62
Support Level $7.09 $16.24
Resistance Level $10.49 $20.15
Average True Range (ATR) 0.14 1.37
MACD 0.05 -0.23
Stochastic Oscillator 64.23 22.61

Price Performance

Historical Comparison
WB
TRVI

About WB Weibo Corporation

Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: